CORONA Remedies has achieved its highest-ever quarterly revenue, registering a stellar 22% year-on-year growth for Q2 FY27 at Rs. 441.2 crore as compared to Rs. 361.1 crore in Q2 FY26.

Profit After Tax (PAT) stood at Rs. 60.3 crore in Q2 FY27 as compared to Rs. 52.3 crore in Q2 FY26, reflecting a growth of 15.3%. EBITDA at Rs. 96 crore also witnessed a jump of 22.3% as compared to Rs. 78.5 crore in Q2 FY26.

For the Half Year ended September 30, 2026, Corona Remedies' revenue from operations surged 22% to Rs. 863.6 crore as compared to Rs. 707.7 crore in H1 FY26. PAT during the H1 FY27 reported at Rs. 120.4 crore as compared to Rs. 98.5 crore in H1 FY27.

This landmark financial performance highlights the company’s accelerating momentum in the highly competitive pharmaceutical landscape, driven by robust volume expansion and strategic therapeutic market penetration.

The impressive 22% growth rate significantly outpaces the broader Indian Pharmaceutical Market (IPM) averages, underscoring CORONA Remedies' resilient business model and the escalating demand for its core product portfolio.

Commenting on the results, Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. Revenue grew 22.2% year-on-year in Q2FY27 and 22% in H1FY27, ahead of our stated guidance. Our domestic business grew at 22.9%, well ahead of the Indian Pharmaceutical Market (IPM) growth of 12%, and our chronic portfolio grew at nearly twice the rate of its market segment.

This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence and investing in capabilities that will support our future growth.

The Indian pharmaceutical industry is underpinned by strong structural demand drivers. Backedby our diversified portfolio, established brands, expanding market reach and experienced leadership team, we are well positioned to capitalise on these opportunities and sustain our growth momentum.”

The company leadership attributed this record-setting quarter to exceptional execution across its diversified therapeutic segments, particularly in high-growth areas such as cardiometabolic health, gynecology, and critical care. Enhanced field force productivity and deepening distribution networks across both metro and tier-2 markets further amplified this revenue surge.